Cpf1 Endonuclease and AAV Vectors for CAR-T Genome Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies face challenges such as limited manufacturing efficiency, immune rejection, rapid cell disappearance, and variable efficacy due to tumor-evolved immune suppression mechanisms, necessitating improved methods for generating stable and potent CAR T cells with reduced exhaustion and enhanced cytotoxic activity.
Innovation Solution
The use of RNA-guided endonucleases like Cpf1 in combination with AAV vectors for multiplex genomic editing, enabling efficient knockout and knock-in of target genes, including disruption of immunosuppressive genes and integration of chimeric antigen receptors (CARs), to enhance CAR T cell stability and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lentiviral and γ-retroviral vectors are used for T cell transgene delivery, then CAR transgene expression can be achieved, but insertional oncogenesis and translational silencing risks occur
Solution Approach 1:
The patent replaces viral vector-based transgene delivery with CRISPR/Cas9-mediated precise genomic integration. Instead of relying on random viral integration, the system uses guide RNAs to direct Cas9 nuclease to specific safe harbor loci (e.g., CCR5, TRAC), enabling controlled and predictable transgene insertion that avoids insertional oncogenesis while maintaining stable CAR expression.
Solution Approach 2:
The patent introduces CRISPR guide RNAs as intermediaries to mediate between the transgene delivery system and the target genome. These guide RNAs direct the Cas9 nuclease to specific genomic locations, serving as molecular mediators that enable precise targeting and integration without the random integration problems of viral vectors.
2Adaptability or versatility
If multiplex gene editing is performed with Cas9 nuclease, then multiple genomic modifications can be achieved, but the manufacturing process becomes complex
Solution Approach 1:
The patent merges multiple gene editing operations into a single CRISPR/Cas9 transduction step. By designing multiple guide RNAs that target different genes (e.g., simultaneous knockout of PD-1, CTLA-4, and TRAC), the system achieves multiplex editing through one unified process, eliminating the need for sequential transductions and electroporations required by traditional methods.
Solution Approach 2:
The patent creates a universal CRISPR/Cas9 platform that can perform multiple functions: knockout of endogenous genes (TRAC, PD-1, CTLA-4), integration of transgenes (CARs), and modulation of immune checkpoint proteins. This single system replaces multiple specialized procedures, simplifying the manufacturing workflow while maintaining versatility.
3Adaptability or versatility
If autologous T cells are used for CAR T therapy, then patient-specific treatment is achieved, but manufacturing time and expense increase
Solution Approach 1:
The patent enables preliminary preparation of universal CAR T cell products with optimized genomic modifications (e.g., TRAC knockout, immune checkpoint modulation) that can be manufactured in advance and stored. When needed, these pre-prepared cells can be rapidly expanded and infused without requiring the full manufacturing timeline, thus reducing treatment time while maintaining patient-specific adaptability through selective expansion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach simplifies the manufacturing process, reduces immune rejection, and increases the stability and cytotoxic activity of CAR T cells, leading to improved clinical efficacy and prolonged CAR transgene expression.
Implementation Method 1
one or more AAV vectors containing a sequence (e.g., a crRNA array) that encodes one or more crRNAs that collectively direct the endonuclease to one or more target genes
Implementation Method 2
modifying the genome of a cell by introducing to the cell an RNA-guided endonuclease and one or more AAV vectors
Implementation Method 3
one or more AAV vectors containing a sequence (e.g., a crRNA array) that encodes one or more crRNAs that collectively direct the endonuclease to one or more target genes
Implementation Method 4
The HDR template can further include a promoter and/or polyadenylation signal operationally linked to each reporter gene, CAR, or combination thereof
Data Source
AI summary
Disclosed are compositions and methods for cellular genome engineering that permit simple, efficient, and versatile permutations of combinatorial or simultaneous knockout and knock-in genomic modifications. An exemplary method includes modifying the genome of a cell by introducing to the cell a Cpf1 endonuclease and one or more AAV vectors encoding one or more crRNAs that direct the endonuclease to one or more target genes. The AAV vectors further contain one or more HDR templates that provide a sequence that encodes a reporter gene, a chimeric antigen receptor (CAR), or combinations thereof, and sequences homologous to one or more target sites. Also disclosed are pharmaceutical compositions containing genetically modified cells and methods of use thereof in treating a subject having a disease or disorder, such as cancer. The disclosed compositions and methods are especially applicable to development of enhanced chimeric antigen receptor engineered T cell therapy (CAR-T).